0.3547

5.63% 0.0189

After Hours: .36 0.0053 +1.49%

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $0.3547, with a volume of 2.47M. It is up +5.63% in the last 24 hours and down -25.95% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Previous Close:

$0.3358

Open:

$0.33

24h Volume:

2.47M

Relative Volume:

0.56

Market Cap:

$41.30M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-0.2365

EPS:

-1.5

Net Cash Flow:

$-171.05M

1W Performance:

+35.69%

1M Performance:

-25.95%

6M Performance:

-83.19%

1Y Performance:

-89.92%

1-Day Range:

$0.33

$0.3802

1-Week Range:

$0.2646

$0.4001

52-Week Range:

$0.2589

$3.63

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

102

Twitter

@MersanaADC

Next Earnings Date

2025-03-03

Latest SEC Filings

MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRSN Mersana Therapeutics Inc	0.3547	41.30M	36.86M	-171.67M	-171.05M	-1.50
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-25	Initiated	William Blair	Outperform
Nov-15-24	Resumed	Citigroup	Buy
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

Apr 14, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Wellington Management Group LLP - Defense World

Apr 14, 2025

Apr 13, 2025

Sei Investments Co. Purchases Shares of 69,527 Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Apr 13, 2025

Apr 08, 2025

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech

Apr 08, 2025

Apr 04, 2025

MRSN stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com

Apr 04, 2025

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025

Mersana Strengthens Team with Strategic 26,790-Share RSU Grant to New Hire - Stock Titan

Apr 04, 2025

MRSN stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 02, 2025

When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com

Apr 02, 2025

Apr 01, 2025

Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire

Apr 01, 2025

FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan

Apr 01, 2025

Mar 28, 2025

Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World

Mar 28, 2025

Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India

Mar 27, 2025

MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st

Mar 27, 2025

Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld MedTech

Mar 21, 2025

Mar 20, 2025

MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India

Mar 20, 2025

Mar 13, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia

Mar 11, 2025

Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada

Mar 11, 2025

MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 10, 2025

Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat

Mar 10, 2025

Mar 08, 2025

Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St

Mar 08, 2025

Mar 07, 2025

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Mar 06, 2025

Mar 05, 2025

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance

Mar 05, 2025

Mar 04, 2025